7056EGP
- Active ingredient
- bevacizumab
- Strength
- 100mg/4ml
- Form
- vial
- Manufacturer
- gypto pharma
- Route
- injection
Uses
Used in combination regimens for various cancers including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and others.
Do not use if
No formal absolute contraindications are listed, but severe hypersensitivity warrants discontinuation.
Side effects
May cause hypertension, bleeding, thromboembolism, proteinuria, wound-healing complications, and gastrointestinal perforation.
Warnings
Monitor for serious bleeding, thromboembolic events, wound-healing complications, and gastrointestinal perforation.
How it works
A monoclonal antibody that binds VEGF and inhibits tumor angiogenesis.
Storage
Store refrigerated at 2°C to 8°C. Do not freeze or shake.